GastroAGI Logo
OverviewBlogsAbout
Trending TopicsConference
Topics/Liver Transplantation/Frailty at 1 Year Predicts Long-Term Mortality After Liver Transplant : Liver Transpl | June 2026

Frailty at 1 Year Predicts Long-Term Mortality After Liver Transplant : Liver Transpl | June 2026

Clinical knowledge base curated and reviewed by GastroAGI TeamLast updated June 1, 2026

Quick Answer

Introduction: Frailty is increasingly recognized as a key determinant of outcomes in patients with advanced liver disease and has become an important component of liver transplant evaluation. Although many patients experience functional recovery after liver transplantation, a subset remain frail or develop new frailty during the post-transplant period.


Introduction:

Frailty is increasingly recognized as a key determinant of outcomes in patients with advanced liver disease and has become an important component of liver transplant evaluation. Although many patients experience functional recovery after liver transplantation, a subset remain frail or develop new frailty during the post-transplant period. The long-term consequences of persistent or newly developed frailty after transplantation have not been well defined.

Problem Statement:

Most studies have focused on pre-transplant frailty, yet little is known about the prognostic significance of frailty after transplantation. Identifying whether post-transplant frailty influences long-term survival and quality of life could help guide follow-up strategies and inform interventions aimed at improving outcomes in liver transplant recipients.

Summary:

This multicenter analysis from the Functional Assessment in Liver Transplantation (FrAILT) Study demonstrates that frailty one year after liver transplantation is a powerful predictor of long-term outcomes. Approximately one in eight transplant recipients remained frail at one year, with frailty occurring more commonly among patients with metabolic dysfunction–associated steatotic liver disease, diabetes, prior frailty, and certain vascular comorbidities. Importantly, frailty at one year was associated with substantially higher long-term mortality and significantly poorer physical health-related quality of life. Even after accounting for other clinical factors, post-transplant frailty remained an independent predictor of adverse outcomes. Particularly noteworthy was the observation that patients who transitioned from a non-frail state before transplantation to a frail state one year later experienced the greatest increase in mortality risk. These findings challenge the assumption that successful transplantation alone eliminates the prognostic impact of frailty and suggest that functional recovery should be considered a major post-transplant outcome. The study highlights the first year after liver transplantation as a critical window for ongoing frailty assessment and intervention. Structured rehabilitation, nutritional optimization, physical activity programs, and targeted management of metabolic comorbidities may represent important opportunities to improve long-term survival and quality of life. Overall, the findings support incorporating routine frailty assessment into post-transplant care and emphasize frailty as a modifiable determinant of long-term transplant success.

Related Q&A

Synbiotics After Liver Transplant Show No Clinical Benefit: Liver Transplant | July 2026

Introduction: Bacterial infections remain a major cause of morbidity after liver transplantation despite advances in perioperative care. Synbiotics, combining probiotics and prebiotics, have been proposed to reduce postoperative infections by restoring gut microbiota and strengthening...

Tranexamic Acid in Liver Transplantation: Liver Transplant | June 2026

Introduction: Perioperative bleeding remains a major challenge during orthotopic liver transplantation (OLT), largely due to hyperfibrinolysis and coagulation abnormalities. Although tranexamic acid (TXA) effectively reduces bleeding in several surgical settings, its routine prophylactic use during...

Whole-Organ Donor Liver Assessment Using PS-OCT: Science Translational Medicine | July 2026

Introduction: Liver transplantation is limited by a shortage of suitable donor organs. Current viability assessment relies on needle biopsy, which samples only a small portion of the liver and may miss important regional pathology. This...

Personalizing Antifibrinolytic Use in Liver Transplantation : Liver Transpl | Jul 2026

Introduction: Bleeding remains a major challenge during liver transplantation despite advances in surgical techniques, anesthesia, and perioperative care. Antifibrinolytic agents have long been used to reduce intraoperative blood loss and transfusion requirements. However, evolving transplant...

Integrating LDLT into Modern Liver Transplant Programs: Liver Transplantation | June 2026

Introduction: The demand for liver transplantation continues to exceed the availability of deceased donor organs, resulting in prolonged waiting times and preventable waitlist mortality. This perspective discusses how living donor liver transplantation (LDLT) can complement...

Post-Transplant Management in Pediatric LT: Liver Transplantation | June 2026

Introduction: Pediatric liver transplantation has achieved excellent survival rates, shifting the focus from graft survival alone to optimising long-term health, growth, neurodevelopment, and quality of life. This updated guideline provides evidence-based recommendations for comprehensive care...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer